• Men or women, Age ≥18 years

• Patients with ECOG performance status 0 or 1

• Patients with histologically confirmed diagnosis of HCC not amenable to curative surgery or local therapy

• Patients with documented objective radiographic progression during or after local therapy or after treatment with sorafenib or lenvatinib or intolerance to or refusal to receive either agent

• Patients with at least one prior systemic therapy for HCC

• Patients eligible to be treated with nivolumab

• Patients with measurable disease based on RECIST v1.1

• Patients with Child-Pugh class A liver score within 7 days of first study dose

• Patients with no history of hepatic encephalopathy

• Patients with no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)

• Patients with HBV infection must have received antiviral therapy for at least 12 weeks and HBV viral load must be documented to be \<100 IU/mL within 7 days of first study dose

• Patients with no active co-infection with HBV and HCV or HBV and HDV

• Patients with no active drug or alcohol abuse